<p>联合治疗公司（NASDAQ: UTHR）将于 2026 年 2 月 25 日发布季度财报。以下是投资者在公告前的简要概述。</p>
<p>分析师预计联合治疗公司将报告每股收益（EPS）为 6.77 美元。</p>
<p>联合治疗公司的多头希望听到公司不仅超出该预期，还能提供积极的指引或下个季度的增长预测。</p>
<p>新投资者应注意，有时影响股票价格的并不是盈利的超出或未达预期，而是指引（或预测）。</p>
<h3>盈利记录</h3>
<p>在上个季度，公司报告的每股收益超出预期 0.23 美元，导致次日股价下跌 0.39%。</p>
<p>以下是联合治疗公司过去表现及其价格变化的概览：</p>
<table>
<thead>
<tr>
<th><strong>季度</strong></th>
<th align="right"><strong>2025 年第三季度</strong></th>
<th align="right"><strong>2025 年第二季度</strong></th>
<th align="right"><strong>2025 年第一季度</strong></th>
<th align="right"><strong>2024 年第四季度</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS 预估</strong></td>
<td align="right">6.93</td>
<td align="right">6.87</td>
<td align="right">6.53</td>
<td align="right">6.31</td>
</tr>
<tr>
<td><strong>EPS 实际</strong></td>
<td align="right">7.16</td>
<td align="right">6.41</td>
<td align="right">6.63</td>
<td align="right">6.19</td>
</tr>
<tr>
<td><strong>价格变化 %</strong></td>
<td align="right">0.00</td>
<td align="right">-3.00</td>
<td align="right">-3.00</td>
<td align="right">1.00</td>
</tr>
</tbody>
</table>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1771945365_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="eps graph" width="700" height="500" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1771945365_0.png"/></p>
<h3>联合治疗公司股价分析</h3>
<p>截至 2 月 23 日，联合治疗公司的股票交易价格为 474.52 美元。在过去 52 周内，股价上涨了 48.05%。考虑到这些回报通常是积极的，长期股东在此次财报发布前可能持乐观态度。</p>
<p>要跟踪联合治疗公司的所有财报发布，请访问我们网站上的财报日历。</p>
<p><em>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</em></p>

联合治疗

<p>联合治疗（NASDAQ:UTHR）计划于 2026 年 2 月 25 日发布季度财报，分析师预计每股收益（EPS）为 6.77 美元。投资者对财报发布后的积极指引抱有希望。在上一个季度，公司每股收益超出预期 0.23 美元，但次日股价下跌了 0.39%。截至 2 月 23 日，股价为 474.52 美元，较去年同期上涨了 48.05%，显示出长期股东的乐观情绪</p>

<p>United Therapeutics (NASDAQ: UTHR) will release its quarterly earnings report on Wednesday, 2026-02-25. Here's a brief overview for investors ahead of the announcement.</p>
<div class="lb-trans"><p>联合治疗公司（NASDAQ: UTHR）将于 2026 年 2 月 25 日发布季度财报。以下是投资者在公告前的简要概述。</p>
</div><p>Analysts anticipate United Therapeutics to report an <strong>earnings per share</strong> (EPS) of $6.77.</p>
<div class="lb-trans"><p>分析师预计联合治疗公司将报告每股收益（EPS）为 6.77 美元。</p>
</div><p>United Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<div class="lb-trans"><p>联合治疗公司的多头希望听到公司不仅超出该预期，还能提供积极的指引或下个季度的增长预测。</p>
</div><p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<div class="lb-trans"><p>新投资者应注意，有时影响股票价格的并不是盈利的超出或未达预期，而是指引（或预测）。</p>
</div><h3>Earnings Track Record</h3>
<div class="lb-trans"><h3>盈利记录</h3>
</div><p>During the last quarter, the company reported an EPS beat by $0.23, leading to a 0.39% drop in the share price on the subsequent day.</p>
<div class="lb-trans"><p>在上个季度，公司报告的每股收益超出预期 0.23 美元，导致次日股价下跌 0.39%。</p>
</div><p>Here's a look at United Therapeutics's past performance and the resulting price change:</p>
<div class="lb-trans"><p>以下是联合治疗公司过去表现及其价格变化的概览：</p>
</div><table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th align="right"><strong>Q3 2025</strong></th>
<th align="right"><strong>Q2 2025</strong></th>
<th align="right"><strong>Q1 2025</strong></th>
<th align="right"><strong>Q4 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td align="right">6.93</td>
<td align="right">6.87</td>
<td align="right">6.53</td>
<td align="right">6.31</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td align="right">7.16</td>
<td align="right">6.41</td>
<td align="right">6.63</td>
<td align="right">6.19</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td align="right">0.00</td>
<td align="right">-3.00</td>
<td align="right">-3.00</td>
<td align="right">1.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th><strong>季度</strong></th>
<th align="right"><strong>2025 年第三季度</strong></th>
<th align="right"><strong>2025 年第二季度</strong></th>
<th align="right"><strong>2025 年第一季度</strong></th>
<th align="right"><strong>2024 年第四季度</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS 预估</strong></td>
<td align="right">6.93</td>
<td align="right">6.87</td>
<td align="right">6.53</td>
<td align="right">6.31</td>
</tr>
<tr>
<td><strong>EPS 实际</strong></td>
<td align="right">7.16</td>
<td align="right">6.41</td>
<td align="right">6.63</td>
<td align="right">6.19</td>
</tr>
<tr>
<td><strong>价格变化 %</strong></td>
<td align="right">0.00</td>
<td align="right">-3.00</td>
<td align="right">-3.00</td>
<td align="right">1.00</td>
</tr>
</tbody>
</table>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1771945365_0.png" alt="eps graph" original-src="https://www.benzinga.com/files/images/story/2026/1771945365_0.png"/></p>
<h3>United Therapeutics Share Price Analysis</h3>
<div class="lb-trans"><h3>联合治疗公司股价分析</h3>
</div><p>Shares of United Therapeutics were trading at $474.52 as of February 23. Over the last 52-week period, shares are up 48.05%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.</p>
<div class="lb-trans"><p>截至 2 月 23 日，联合治疗公司的股票交易价格为 474.52 美元。在过去 52 周内，股价上涨了 48.05%。考虑到这些回报通常是积极的，长期股东在此次财报发布前可能持乐观态度。</p>
</div><p>To track all earnings releases for United Therapeutics visit their earnings calendar on our site.</p>
<div class="lb-trans"><p>要跟踪联合治疗公司的所有财报发布，请访问我们网站上的财报日历。</p>
</div><p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>
<div class="lb-trans"><p><em>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</em></p>
</div>

前瞻洞察：United Therapeutics 的季度财报